CA
NZ
UK
AU
IND
US
Shares are giving back a portion of an extraordinary year-to-date run as investors reassess valuation after a 90-day return of over 36% and a 1-year gain of nearly 160%. Analysts have flagged the stock's elevated P/E of roughly 81x, well above the broader Communications …
A broader semiconductor sector selloff pressures the stock, with TD Cowen cutting its price target to $95 from $110 while maintaining a Hold rating. The decline comes amid sector-wide weakness, with the Philadelphia Semiconductor Index down more than 11% from its June record high.
Analyst sentiment remains mixed following a strong recent run: Morgan Stanley reaffirmed its Equal Weight rating with a $75 price target, after previously downgrading the stock from Overweight citing a roughly 50% surge in a month. Jim Cramer noted he'd need to see profitability …
The decline follows a Q1 earnings miss, with EPS of -$0.45 versus -$0.39 expected and revenue of just $4.21 million against a $10.95 million projection. Notable insider selling of more than 81,000 shares over the past 90 days has weighed further on investor confidence.
Shares are underperforming broader solar peers as renewed U.S.-Iran tensions rattled equity markets and weighed on risk sentiment across clean energy names. The selloff compounds existing headwinds for the solar sector, including a projected first year of negative global PV demand growth in over …
Broader risk-off sentiment, driven by renewed U.S.-Iran tensions and a chip sector selloff, compounds the stock's prolonged decline from its October 2025 peak. Despite today's analyst reaffirmation from Texas Capital with a Buy rating and $93 price target, mounting concerns over insider stock sales, …
Bearish analyst pressure has been mounting, with Citi naming Adobe among its least-favored software stocks ahead of Q2 earnings, citing execution risks and slowing bookings growth, while Bank of America initiated coverage with an Underperform rating and $190 target. Despite this, shares still down …
The stock tumbled amid investor scrutiny over an insider sale by the Chief Scientific Officer of Ophthalmology, who sold 27,659 shares on July 7, just ahead of two anticipated drug filings. The selling has raised valuation questions after the stock's roughly 50% run over …
Renewed U.S.-Iran tensions, surging oil prices, and major bank earnings kicking off this week are weighing on higher-beta fintech names broadly. Q1 results showed revenue up 42.6% year-over-year, and Goldman Sachs recently raised its price target on the stock to $21.
The pullback comes despite a notable institutional vote of confidence, as Candriam S.C.A. disclosed a new 773,620-share position worth approximately $9.2 million in Q1 filings reported today. Analysts maintain a consensus Buy rating with an average price target of $22.67, well above current trading …
Please wait processing your request...